ArticleLeukemia2023
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Application of next-generation sequencing in the treatment of myelodysplastic syndrome: from mechanisms to clinical practice.Blood science (Baltimore, Md.) · 2026Review
- Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.Blood advances · 2026Article
- Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms.Leukemia · 2026Article
- A comparative assessment of molecular-based prognostic models in CMML.Blood neoplasia · 2025Article
- A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia.Blood cancer journal · 2025Article
- Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?Leukemia · 2025Article
- Favorable outcomes and the association between dynamic transfusion dependence and IPSS-M in MDS-h and MDS-LB patients undergoing allo-HSCT.Bone marrow transplantation · 2025Article
- Advances and challenges in the treatment of myelodysplastic syndromes.Experimental hematology & oncology · 2025Review
- Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.Blood neoplasia · 2025Article
- How I treat higher-risk MDS.Blood · 2025Review
- Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes.Annals of hematology · 2025Article
- Article
- Review
- Article
- How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.Hematology. American Society of Hematology. Education Program · 2023Article
- Frontline treatment options for higher-risk MDS: can we move past azacitidine?Hematology. American Society of Hematology. Education Program · 2023Article
- Threefold IPSS-M reclassification outperforms original stratification in predicting post-transplant outcomes for MDS patients.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS-R by incorporating mutational data. The model showed improved prognostic accuracy over the IPSS-R across three endpoints: overall survival (OS), leukemia-free survival (LFS) and leukemic transformation. This study aimed to validate the findings of the original in a large cohort of MDS patients, as well as assess its validity in therapy-related and hypoplastic MDS. We retrospectively reviewed clinical, cytogenetic and molecular data for 2355 MDS patients treated at the Moffitt Cancer Center. Correlative analysis between IPSS-R and mean IPSS-M scores and outcome predictions was performed on LFS, OS and leukemic transformation. Using the IPSS-M, patients were classified as Very Low (4%), Low (24%), Moderate-Low (14%), Moderate-High (11%), High (19%) and Very-High risk (28%). Median OS was 11.7, 7.1, 4.4, 3.1, 2.3, and 1.3 years from VL to VH risk subgroups. Median LFS was 12.3, 6.9, 3.6, 2.2, 1.4, and 0.5 years respectively. For patients with t-MDS and h-MDS the model retained its prognostic accuracy. Generalized use of this tool will likely result in more accurate prognostic assessment and optimize therapeutic decision-making in MDS.
Indexed as
Identifiers
37147425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.